Next Article in Journal
Comparative Evaluation of Mechanical and Physical Properties of Mycelium Composite Boards Made from Lentinus sajor-caju with Various Ratios of Corn Husk and Sawdust
Previous Article in Journal
Comparative Genomics of Fungi in Nectriaceae Reveals Their Environmental Adaptation and Conservation Strategies
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Epidemiology of Onychomycosis in the United States Characterized Using Molecular Methods, 2015–2024

by
Aditya K. Gupta
1,2,*,
Tong Wang
2,
Shruthi Polla Ravi
2,
Avantika Mann
2,
Sara A. Lincoln
3,
Hui-Chen Foreman
3 and
Wayne L. Bakotic
3
1
Division of Dermatology, Department of Medicine, Temerty Faculty of Medicine, University of Toronto, Toronto, ON M5S 3H2, Canada
2
Mediprobe Research Inc., London, ON N5X 2P1, Canada
3
Bako Diagnostics, Alpharetta, GA 30005, USA
*
Author to whom correspondence should be addressed.
J. Fungi 2024, 10(9), 633; https://doi.org/10.3390/jof10090633
Submission received: 2 August 2024 / Revised: 27 August 2024 / Accepted: 31 August 2024 / Published: 5 September 2024
(This article belongs to the Special Issue Personalized Mycology)

Abstract

:
Onychomycosis is a recalcitrant fungal infection of the nail unit that can lead to secondary infections and foot complications. Accurate pathogen identification by confirmatory testing is recommended to improve treatment outcomes. In this study, we reviewed the records of 710,541 patients whose nail specimens were sent to a single molecular diagnostic laboratory between 2015 and 2024. PCR testing revealed a more comprehensive spectrum of pathogens than previously reported, which was corroborated by the demonstration of fungal invasion on histopathology. Consistent with our current understanding, the T. rubrum complex (54.3%) are among the most common pathogens; however, a significant portion of mycology-confirmed diagnoses were caused by the T. mentagrophytes complex (6.5%), Aspergillus (7.0%) and Fusarium (4.5%). Females were significantly more likely to be infected with non-dermatophytes molds (NDMs; OR: 2.0), including Aspergillus (OR: 3.3) and Fusarium (OR: 2.0), and yeasts (OR: 1.5), including Candida albicans (OR: 2.0) and C. parapsilosis (OR 1.6), than males. The T. mentagrophytes complex became more prevalent with age, and conversely the T. rubrum complex became less prevalent with age. Patients aged ≥65 years also demonstrated a higher likelihood of contracting onychomycosis caused by NDMs (OR: 1.6), including Aspergillus (OR: 2.2), Acremonium (OR: 3.5), Scopulariopsis (OR: 2.9), Neoscytalidium (OR: 3.8), and yeasts (OR: 1.8), including C. albicans (OR: 1.9) and C. parapsilosis (OR: 1.7), than young adults. NDMs (e.g., Aspergillus and Fusarium) and yeasts were, overall, more likely to cause superficial onychomycosis and less likely to cause dystrophic onychomycosis than dermatophytes. With regards to subungual onychomycosis, Aspergillus, Scopulariopsis and Neoscytalidium had a similar likelihood as dermatophytes. The advent of molecular diagnostics enabling a timely and accurate pathogen identification can better inform healthcare providers of appropriate treatment selections and develop evidence-based recommendations.

1. Introduction

Toenail onychomycosis represents a difficult-to-treat form of superficial fungal infections [1]. The management of this chronic, slow-progressive condition is complicated by long treatment durations (often more than a year) and a high risk of recurrence (20–25%) [2]. The prevalence of onychomycosis is estimated at 4% globally, with a disproportionate burden among special populations [3]. With a myriad of treatment options available, from oral and topical antifungals to over-the-counter products and lasers, complete cure rates for onychomycosis (i.e., eradication of fungal infection with normal-appearing nails) remain sub-optimal, highlighting the need for tailored treatments [2,4].
Onychomycosis is primarily caused by dermatophytes with Trichophyton rubrum being the most frequently reported pathogen. However, an infection by non-dermatophyte molds (NDMs) and yeasts are considered negative prognostic factors owing to their varied antifungal susceptibility profiles (e.g., terbinafine vs. itraconazole as first-line treatments), as well as diagnostic challenges that can cause treatment delays [5,6,7,8]. Traditional onychomycosis diagnosis by fungal culture has significant limitations due to the slow turnaround time (2–4 weeks) and low sensitivity; with NDMs and yeasts, there is an added challenge of requiring repeated culture isolations, which can further delay treatment initiation [9,10].
In recent years, molecular diagnostics by polymerase chain reaction (PCR) has become available for the speciation of infecting fungal agents. A multiplexed PCR assay design, in particular, can simultaneously detect multiple fungal agents with a 1–2-day turnaround time. The combined use of PCR with histopathologic examination has been recommended as a reliable diagnostic method as it enables pathogen identification with a direct demonstration of nail plate invasion [11]. In this study, we aim to update our current understanding of the epidemiology of onychomycosis in the United States by using a combination of molecular diagnosis through a multiplex real-time PCR assay and histopathologic examination.

2. Materials and Methods

Records of all nail specimens submitted to a CLIA-certified, molecular diagnostic laboratory (Bako Diagnostics, Alpharetta, GA, USA) were reviewed. This cohort represents clinically suspected onychomycosis patients seen by dermatologists and podiatrists across the United States. The inclusion criteria were specimens subjected to confirmatory testing by multiplex real-time PCR and histopathologic examination as per a physician’s order; specimens subjected to a single test only, or by fungal culture, were excluded. This study constitutes a review of secondary, de-identified diagnostic data. All procedures were provided by a CLIA-certified laboratory as a part of routine care; as such, these do not represent a clinical trial for which ethics oversight and informed consent are required.

2.1. Multiplex Real-Time PCR

DNA extraction and multiplex real-time PCR (BakoDx Onychodystrophy Agent Detection) were performed, as previously described [12,13]. DNA extracts were subjected to two sequential multiplex real-time PCR panels for detection and identification (QuantStudioTM 6, Life Technologies, Carlsbad, CA, USA). The detection panel included dermatophytes, NDMs, and yeasts. The dermatophyte identification panel included the T. rubrum complex (T. rubrum, T. violaceum), the T. mentagrophytes complex (T. benhamiae, T. indotineae, T. interdigitale, T. mentagrophytes, T. tonsurans), Microsporum and Epidermophyton. The NDM identification panel included Acremonium, Alternaria, Aspergillus, Curvularia, Fusarium, Scopulariopsis and Neoscytalidium. The yeast identification panel included Candida albicans, C. guilliermondii, C. parapsilosis, C. tropicalis, Cryptococcus, Malassezia, and Trichosporon.

2.2. Histopathology

Nail specimens were stained by Periodic acid–Schiff (PAS) and/or Grocott’s methenamine silver (GMS) and reviewed by a dermatopathologist. Infection patterns were identified as either subungual (infiltrating fungal elements within the subungual keratin only); superficial (infiltrating fungal elements across the superficial keratin layers of the nail plate); or dystrophic (infiltrating fungal elements through the nail plate and subungual keratin) (Figure 1). Fungal element quantities were categorized as rare (sparse fungal elements primary in the subungual region with little to no association with nail keratin); minimal (<10% of submitted nail keratin involvement); moderate (10–80% of submitted nail keratin involvement); or florid (>80% of submitted nail keratin involvement) [12].

2.3. Data Analysis

A positive, mycology-confirmed onychomycosis diagnosis was defined as samples testing positive by PCR with demonstration of fungal invasion on histopathologic examination. The analysis of patient characteristics was restricted to unique patients; repeat samples were removed. For patients with multiple specimens collected, only the first specimen was included. Analysis of histopathologic examination results included all specimens. Mixed infections were not analyzed due to the inability to match positive histopathologic results with one or the other fungal agents detected.
Data curation and analyses were performed using Microsoft Excel (version 2301). Patient demographics (age, sex, U.S. census region), PCR, and histopathologic examination results were tabulated. Relationships between patient characteristics, pathogen identification results and histopathologic examination results were quantified using the odds ratio (OR) and 95% confidence interval (CI); two-sided p-values were calculated as previously described by Altman and Bland [14]. A p-value of 0.05 was considered statistically significant.

3. Results

Records were retrieved from 710,541 patients (797,560 specimens), with a clinical diagnosis of onychomycosis, from March 2015 to April 2024 (9 years and 2 months). When assessing results stratified by year, the mean positivity rate—per PCR and histopathologic examination—was 51.0% (standard deviation [SD]: 2.8). Dermatophytes consistently accounted for the highest proportion of mycology-confirmed onychomycosis diagnoses (Mean [SD]: 63.7% [4.6]; Range, 55.4–69.0%) followed by NDMs (Mean [SD]: 20.1% [4.9]; Range, 14.6–30.7%), and yeasts (Mean [SD]: 6.2% [0.8]; Range, 4.5–6.8%). The T. rubrum complex were the most common dermatophytes detected, Aspergillus and Fusarium were the most common NDMs detected, and C. parapsilosis was the common yeast detected (Figure 2). No significant temporal changes were observed.

3.1. Sex Differences

As shown in Table 1, Table 2 and Table 3, females exhibited a 70% lower odds of contracting dermatophyte onychomycosis than males (OR: 0.3 [95% CI: 0.3, 0.3], p < 0.001). Conversely, females were twice as likely to contract NDM onychomycosis (OR: 2.0 [95% CI: 1.9, 2.0], p < 0.001), and had 50% higher odds of contracting yeast onychomycosis (OR: 1.5 [95% CI: 1.5, 1.6], p < 0.001), than males.
Among NDMs, Aspergillus and Fusarium were the most common. Females were three times more likely to be detected with Aspergillus (OR: 3.3 [95% CI: 3.1, 3.4], p < 0.001), and twice as likely to be detected with Fusarium (OR: 2.0 [95% CI: 1.9, 2.1], p < 0.001), than males. Similarly, for yeasts, females were twice as likely to be detected with C. albicans (OR: 2.0 [95% CI: 1.8, 2.2], p < 0.001), as well as 60% higher odds for C. parapsilosis (OR: 1.6 [95% CI: 1.6, 1.7], p < 0.001), than males.

3.2. Age Differences

An age-dependent increase was observed concerning onychomycosis caused by T. mentagrophytes complex, NDMs, and yeasts (Table 1, Table 2 and Table 3). Among dermatophytes, the elderly (≥65 years) showed 50% lower odds (OR: 0.5 [95% CI: 0.5, 0.5], p < 0.001) of contracting onychomycosis caused by the T. rubrum complex than young adults (18–44 years). Conversely, this patient group showed an almost 4-fold increase in the likelihood of contracting onychomycosis caused by the T. mentagrophytes complex (OR: 3.9 [95% CI: 3.7, 4.1], p < 0.001). Similar findings were seen for older adults (45–64 years) compared to younger adults (18–44 years). The T. mentagrophytes complex was significantly less likely to be found among children (OR: 0.2 [95% CI: 0.2, 0.3], p < 0.001).
An age-dependent increase was observed for NDM onychomycosis. The elderly were more likely to contract onychomycosis caused by Aspergillus (OR: 2.2 [95% CI: 2.1, 2.3], p < 0.001), Acremonium (OR: 3.5 [95% CI: 2.8, 4.4], p < 0.001), Scopulariopsis (OR: 2.9 [95% CI: 2.3, 3.6], p < 0.001), and Neoscytalidium (OR: 3.8 [3.2, 4.4], p < 0.001), but not Fusarium (OR: 0.7 [95% CI: 0.7, 0.7], p < 0.001), compared to young adults. For yeasts, both C. albicans (OR: 1.9 [95% CI: 1.7, 2.2], p < 0.001) and C. parapsilosis (OR: 1.7 [1.6, 1.8], p < 0.001) were more frequently detected in the elderly compared to young adults.

3.3. Regional Differences

No significant regional differences were found overall for dermatophytes, NDMs, yeasts, and mixed infections (Table 1, Table 2 and Table 3). Among the NDMs, Aspergillus was more commonly detected in the U.S. South compared to the Midwest (OR: 1.7 [95% CI: 1.6, 1.8], p < 0.001). In contrast, Acremonium (OR: 0.8 [95% CI: 0.7, 0.9], p = 0.005) and Scopulariopsis (OR: 0.5 [95% CI: 0.5, 0.6], p < 0.001) were less likely to be detected in the U.S. South. Neoscytalidium was more likely to be detected in the U.S. Northeast (OR: 4.8 [95% CI: 3.9, 5.9], p < 0.001), South (OR: 3.0 [2.4, 3.7], p < 0.001) and West (OR: 1.8 [95% CI: 1.4, 2.4], p < 0.001), compared to the Midwest.
Among yeasts, no regional differences were found for C. albicans. For C. parapsilosis, it was more likely to be detected in the U.S. Northeast (OR: 1.5 [95%: 1.4, 1.6], p < 0.001) and South (OR: 1.5 [95%: 1.4, 1.6], p < 0.001), compared to the Midwest.

3.4. Differentiation of NDMs and Yeasts on Histopathologic Examination

To assess the pathogenic potentials of NDMs and yeasts, the likelihoods of causing subungual, superficial, or dystrophic onychomycosis were quantified with dermatophytes as the reference group (Figure 3, Figure 4 and Figure 5). Due to the distinct possibility of contaminant or commensal organisms in the subungual keratin (Figure 1), a positive NDM or yeast specimen with the subungual infection pattern was only considered if moderate-to-florid fungal element quantities were present. All samples exhibiting a superficial or dystrophic patterned infection were included in the analysis, as fungal elements were observed to penetrate the nail plate (Figure 1).
After controlling for moderate-to-florid fungal element quantities, Aspergillus, Scopulariopsis and Neoscytalidium exhibited a similar degree of likelihood (p > 0.05) in causing a subungual patterned infection as dermatophytes (Figure 3A). Fusarium exhibited a 16% lower likelihood than dermatophytes (OR: 0.84 [95% CI: 0.81, 0.88], p < 0.001). In contrast, all yeasts were less likely to cause a subungual infection (Figure 3B). The highest relative probability was found in C. albicans (OR: 0.86 [95% CI: 0.79, 0.95], p = 0.002).
All NDMs and yeasts were more likely to cause a superficial patterned infection, and less likely to cause a dystrophic patterned infection, than dermatophytes (Figure 4 and Figure 5). However, we observed differences in likelihood between NDM and yeast species. Fusarium, Scopulariopsis and Neoscytalidium demonstrated a lower likelihood of causing a superficial infection (OR: 2.1–3.5) compared to Acremonium, Aspergillus, Alternaria, and Curvularia (OR: 5.7–9.1) (Figure 4A). Alternaria and Curvularia had a lower likelihood of causing a dystrophic infection (OR: 0.13–0.2) than all other NDM species (Acremonium, Aspergillus, Fusarium, Scopulariopsis, Neoscytalidium) (OR: 0.51–0.71) (Figure 5A). C. albicans (OR: 0.42) could be differentiated from non-albicans Candida (OR: 0.12) as well as Malassezia (OR: 0.16) and Trichosporon (OR: 0.21), with a higher likelihood of causing dystrophic onychomycosis (Figure 5B).

4. Discussion

Treatment decision-making for onychomycosis patients often does not take pathogen identification into consideration [15,16]; this is partially due to a lack of uptake in confirmatory testing and methodological limitations [17,18]. Although not commonly found in onychomycosis patients, an infection by NDMs or yeasts is more difficult to treat [5]. In view of the current treatment paradigm often necessitating long-term maintenance and prophylactic regimens—with varying monthly costs ($8–$1542), efficacy rates and safety concerns—an accurate identification of the causative pathogen should be considered to optimize treatment outcome and improve patient satisfaction [2,4,19].
In this study, we report a detailed analysis of the pathogen spectrum in onychomycosis patients by PCR diagnosis, which was corroborated based on the demonstration of fungal invasion on histopathologic examination. Historically, the rise in onychomycosis is closely linked to the intercontinental spread of T. rubrum replacing T. mentagrophytes as the dominant pathogen in the 20th century [20]. However, our results showed that the T. rubrum complex was only detected in 54.3% of the mycology-confirmed cases. Mono-infections caused by Aspergillus accounted for 7.0% of the mycology-confirmed cases, followed by Fusarium at 4.5%, and C. parapsilosis at 3.5% (Figure 2). A similar relative distribution was observed in previous epidemiology studies conducted in the United States and Canada [21,22].
Due to differences in methodology—especially if there is a lack of repeat sampling to confirm the presence of NDMs or yeasts isolated on culture, or the lack of a histopathologic examination to demonstrate hyphal invasion—our findings are not directly comparable to other epidemiological surveys of onychomycosis. However, a survey in France (2018–2019) found a rise in cases of Fusarium toenail onychomycosis (13.2% [16/121]) [23], which were detected by fungal culture and identified by MALDI-TOF mass spectrometry; a survey in Spain (2020–2021) found a high prevalence of Candida spp. in onychomycosis involving the hallux (13.2% [5/38]) [24], which was detected by fungal culture and identified by PCR.
Furthermore, we identified trends suggesting that these underrecognized pathogens are more likely to be detected in specific patient groups and geographical regions. Even though male patients have been traditionally considered to have a higher risk for contracting onychomycosis [20], there was a differential pathogen profile between the sexes. Specifically, males were significantly more likely to have a dermatophyte infection, whereas females were more likely to contract NDM onychomycosis by Aspergillus and Fusarium as well as Candida onychomycosis (Table 1, Table 2 and Table 3). Aspergillus was more frequently found in the U.S. South. Through comparison of infection patterns on histopathology, Aspergillus was just as likely to cause a subungual infection as dermatophytes, followed by Fusarium (Figure 3A). All NDMs were more likely to cause superficial onychomycosis than dermatophytes. Both Aspergillus and Fusarium were less likely to cause a dystrophic infection than dermatophytes (Figure 5); however, their likelihood was higher compared to the other NDMs detected.
The underlying cause for the higher likelihood of NDM and yeast onychomycosis in female patients remains unclear. It can be postulated from previous case studies that this may be due to a higher likelihood of nail (micro)trauma secondary to the use of ill-fitting, open-toed footwear [25,26,27]. Hirose et al. reviewed 26 cases of Aspergillus onychomycosis reported across Japan, of which 25 cases were female patients [25]. A recent review also identified a higher propensity for females to contract Fusarium onychomycosis than males (66.3% vs. 24.4%), but the reasons are not specified [6].
Although advanced age has been consistently reported as a significant risk factor for developing onychomycosis [3], we found an age-dependent decrease in the prevalence of the T. rubrum complex and inversely an age-dependent increase in the T. mentagrophytes complex, NDMs, and yeasts (Table 1, Table 2 and Table 3). Among NDMs, we found a higher propensity for Aspergillus, Acremonium, Scopulariopsis and Neoscytalidium infections in the 45–64-year and ≥65-year age groups. For yeasts, C. albicans and C. parapsilosis were also more prevalent in the 45–64-year and ≥65-year age groups. Poor peripheral circulation, comorbidities, brittle nails, and increased (micro)trauma are predisposing factors in this patient group. Further research is warranted to explain these differential detection rates.
Candida onychomycosis is thought to affect predominately fingernails causing opportunistic infections [28]. Its diagnostic criteria is ambiguous [10], and its pathogenic potential is unclear. In this study, we found yeasts (e.g., C. albicans, non-albicans Candida) to more likely cause superficial onychomycosis, and to less likely cause subungual or dystrophic onychomycosis, than dermatophytes. C. albicans, in particular, stands out with the highest relative likelihood of causing dystrophic onychomycosis (Figure 5B). This finding is in agreement with the study by Otašević et al. [29], in which 137 cases of Candida finger- and toenail onychomycosis were analyzed; C. albicans was the only species found in patients presenting with nail dystrophy and paronychia, which was attributed to its potential of transforming into hyphal forms. Other surveillance studies have reported similar findings, where Candida onychomycosis is more common among females and the elderly, with C. parapsilosis being the dominant Candida species [30,31,32].
Taken together, the results of the present study revealed that a significant portion of mycology-confirmed onychomycosis diagnoses are caused by underrecognized pathogens that disproportionately affect females and the elderly. Contrary to our current understanding of onychomycosis, females—who are underrepresented in clinical trials—should not be considered as a low-risk group owing to their higher propensity for contracting NDM and yeast infections [33]. Although older patients are generally at a higher risk for onychomycosis, they were less likely to be affected by the dominant dermatophytic pathogen (T. rubrum complex). The goal of onychomycosis treatment should be to eradicate the fungal infection [11]; a rapid diagnosis by PCR-enabling pathogen identification, with infection pattern characterization by histopathology, provides healthcare providers with the opportunity to make tailored treatment decisions.

Limitations

Our findings are limited by the retrospective study design and diagnostic samples that were submitted to a single laboratory. Given that confirmatory testing is currently offered to only 15.3% of suspected onychomycosis patients [18], our cohort may overrepresent patients with a higher disease burden than the background population. Other predisposing factors to developing onychomycosis, such as comorbidities, family history, occupations and social determinants [34,35,36], could not be analyzed in the present study; further works are much needed to update our current understanding of the epidemiology of onychomycosis. We also recognize that PCR testing for onychomycosis is currently more widely available in developed countries; continued advocacy efforts are warranted to expand the access of this platform in place of fungal culture to improve diagnostic effectiveness.
Lastly, in order to decrease the risk of detecting NDMs or yeasts as non-pathogenic organisms in the subungual space without association to the nail plate or nail keratin invasion, we attempted to correlate PCR results with histopathologic findings both in terms of infection pattern (Figure 1) and fungal element quantities. Specifically, when a subungual patterned infection is observed concurrent with the detection of NDMs or yeasts, we restricted the dataset to only specimens with moderate-to-florid fungal element quantities; in other words, specimens with rare-to-minimal fungal element quantities were excluded if they showed a subungual patterned infection, as we judged these samples to have more potential to represent commensal organisms or contaminants. However, the same restriction was not applied to samples exhibiting a superficial or dystrophic patterned infection since they clearly demonstrate the presence of fungal elements within the nail plate keratin, indicative of keratinolytic activities (Figure 1). In cases where rare or minimal fungal growth is in association with nail keratin invasion and histopathology-defined disease, we judged this observation to be more likely a result of the sampling artifact (i.e., the submitted nail specimen represents an infection area with a reduced fungal load than the rest of the affected nail plate).
When the analysis included all subungual patterned infections, irrespective of fungal element quantities, or only in samples with rare-to-minimal quantities, we observed that most, if not all, the NDMs exhibited a higher likelihood of causing a subungual infection than dermatophytes, which was likely due to a higher prevalence of non-pathogens (Gupta et al., unpublished data [37]). In contrast, when we applied the moderate-to-florid fungal element quantities restriction (Figure 3), Aspergillus, Fusarium, Scopulariopsis and Neoscytalidium exhibited higher likelihoods—indicating a higher pathogenic potential—than Acremonium, Alternaria and Curvularia. This approach remains to be clinically validated with treatment outcomes.

5. Conclusions

Onychomycosis is a significant global healthcare burden complicated by an ever-changing pathogen spectrum that underlies treatment challenges. Although NDMs and yeasts are traditionally considered as uncommon pathogens, we identified a higher risk skewed towards female patients and the elderly. To our knowledge, clinical trials have not been conducted to assess the treatment efficacy of dermatophyte onychomycosis vis-à-vis NDM or yeast onychomycosis; the advent of rapid molecular diagnostics by PCR, with infection pattern characterization by histopathology, may assist healthcare providers in developing evidence-based recommendations.

Author Contributions

Conceptualization, A.K.G. and W.L.B.; methodology, S.A.L., H.-C.F. and W.L.B.; validation, S.A.L., H.-C.F. and W.L.B.; formal analysis, T.W.; investigation, S.A.L., H.-C.F. and W.L.B.; resources, A.K.G. and W.L.B.; data curation, T.W., S.P.R. and A.M.; writing—original draft preparation, T.W.; writing—review and editing, A.K.G., S.P.R., A.M., S.A.L., H.-C.F. and W.L.B.; visualization, T.W.; supervision, A.K.G. and W.L.B.; project administration, A.K.G., T.W. and W.L.B. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

All samples were provided by a qualified medical diagnosis laboratory as part of a non-interventional standard-of-care procedure. We reviewed secondary deidentified data only; as such, the current work does not represent a clinical trial for which ethics overview and informed consent was required.

Informed Consent Statement

Patient consent was waived due to the non-interventional, observational design of our study; no patient identifiers were collected.

Data Availability Statement

Restrictions apply to the availability of these data. Data were obtained from Bako Diagnostics (Alpharetta, GA, USA) and are available from A.K.G. with the permission of Bako Diagnostics.

Conflicts of Interest

Authors Sara A. Lincoln, Hui-Chen Foreman and Wayne L. Bakotic were employed by Bako diagnostics. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

  1. Ghannoum, M.; Isham, N. Fungal Nail Infections (Onychomycosis): A Never-Ending Story? PLoS Pathog. 2014, 10, e1004105. [Google Scholar] [CrossRef] [PubMed]
  2. Falotico, J.M.; Lipner, S.R. Updated Perspectives on the Diagnosis and Management of Onychomycosis. Clin. Cosmet. Investig. Dermatol. 2022, 15, 1933–1957. [Google Scholar] [CrossRef] [PubMed]
  3. Gupta, A.K.; Wang, T.; Polla Ravi, S.; Mann, A.; Bamimore, M.A. Global Prevalence of Onychomycosis in General and Special Populations: An Updated Perspective. Mycoses 2024, 67, e13725. [Google Scholar] [CrossRef] [PubMed]
  4. Gupta, A.K.; Venkataraman, M.; Bamimore, M.A. Relative Impact of Traditional vs. Newer Oral Antifungals for Dermatophyte Toenail Onychomycosis: A Network Meta-Analysis Study. Br. J. Dermatol. 2023, 189, 12–22. [Google Scholar] [CrossRef]
  5. Lipner, S.R.; Scher, R.K. Prognostic Factors in Onychomycosis Treatment. J. Infect. Dis. Ther. 2014, 3, 202. [Google Scholar] [CrossRef]
  6. Uemura, E.V.G.; Barbosa, M.D.S.; Simionatto, S.; Al-Harrasi, A.; Al-Hatmi, A.M.S.; Rossato, L. Onychomycosis Caused by Fusarium Species. J. Fungi 2022, 8, 360. [Google Scholar] [CrossRef]
  7. Bongomin, F.; Batac, C.R.; Richardson, M.D.; Denning, D.W. A Review of Onychomycosis Due to Aspergillus Species. Mycopathologia 2018, 183, 485–493. [Google Scholar] [CrossRef] [PubMed]
  8. Evans, E.G. Resistance of Candida Species to Antifungal Agents Used in the Treatment of Onychomycosis: A Review of Current Problems. Br. J. Dermatol. 1999, 141, 33–35. [Google Scholar] [CrossRef]
  9. Gupta, A.K.; Wang, T.; Cooper, E.A.; Summerbell, R.C.; Piguet, V.; Tosti, A.; Piraccini, B.M. A Comprehensive Review of Nondermatophyte Mould Onychomycosis: Epidemiology, Diagnosis and Management. J. Eur. Acad. Dermatol. Venereol. 2024, 38, 480–495. [Google Scholar] [CrossRef]
  10. Daniel, C.R.; Gupta, A.K.; Daniel, M.P.; Sullivan, S. Candida Infection of the Nail: Role of Candida as a Primary or Secondary Pathogen. Int. J. Dermatol. 1998, 37, 904–907. [Google Scholar] [CrossRef]
  11. Nenoff, P.; Reinel, D.; Mayser, P.; Abeck, D.; Bezold, G.; Bosshard, P.P.; Brasch, J.; Daeschlein, G.; Effendy, I.; Ginter-Hanselmayer, G.; et al. S1 Guideline Onychomycosis. J. Dtsch. Dermatol. Ges. 2023, 21, 678–692. [Google Scholar] [CrossRef]
  12. Gupta, A.K.; Cooper, E.A.; Wang, T.; Lincoln, S.A.; Bakotic, W.L. Single-Point Nail Sampling to Diagnose Onychomycosis Caused by Non-Dermatophyte Molds: Utility of Polymerase Chain Reaction (PCR) and Histopathology. J. Fungi 2023, 9, 671. [Google Scholar] [CrossRef] [PubMed]
  13. Gupta, A.K.; Wang, T.; Cooper, E.A.; Lincoln, S.A.; Foreman, H.-C.; Scherer, W.P.; Bakotic, W.L. Clinical Diagnosis and Laboratory Testing of Abnormal Appearing Toenails: A Retrospective Assessment of Confirmatory Testing for Onychomycosis in the United States, 2022–2023. J. Fungi 2024, 10, 149. [Google Scholar] [CrossRef] [PubMed]
  14. Altman, D.G.; Bland, J.M. How to Obtain the Confidence Interval from a P Value. BMJ 2011, 343, d2090. [Google Scholar] [CrossRef]
  15. Lipner, S.R.; Joseph, W.S.; Vlahovic, T.C.; Scher, R.K.; Rich, P.; Ghannoum, M.; Daniel, C.R.; Elewski, B. Therapeutic Recommendations for the Treatment of Toenail Onychomycosis in the US. J. Drugs Dermatol. 2021, 20, 1076–1084. [Google Scholar] [CrossRef] [PubMed]
  16. Frazier, W.T.; Santiago-Delgado, Z.M.; Stupka, K.C. Onychomycosis: Rapid Evidence Review. Am. Fam. Physician 2021, 104, 359–367. [Google Scholar]
  17. Lim, S.S.; Ohn, J.; Mun, J.-H. Diagnosis of Onychomycosis: From Conventional Techniques and Dermoscopy to Artificial Intelligence. Front. Med. 2021, 8, 637216. [Google Scholar] [CrossRef]
  18. Gold, J.A.W.; Wu, K.; Jackson, B.R.; Benedict, K. Opportunities to Improve Guideline Adherence for the Diagnosis and Treatment of Onychomycosis: Analysis of Commercial Insurance Claims Data, United States. J. Am. Acad. Dermatol. 2023, 88, 683–686. [Google Scholar] [CrossRef]
  19. Roster, K.; Wang, Y.; Lipner, S.R. Retrospective Analysis of Onychomycosis Prescribing Patterns Using the Medicare Part D Prescribers Database 2016–2020. Mycoses 2024, 67, e13660. [Google Scholar] [CrossRef]
  20. Thomas, J.; Jacobson, G.A.; Narkowicz, C.K.; Peterson, G.M.; Burnet, H.; Sharpe, C. Toenail Onychomycosis: An Important Global Disease Burden. J. Clin. Pharm. Ther. 2010, 35, 497–519. [Google Scholar] [CrossRef]
  21. Ghannoum, M.A.; Hajjeh, R.A.; Scher, R.; Konnikov, N.; Gupta, A.K.; Summerbell, R.; Sullivan, S.; Daniel, R.; Krusinski, P.; Fleckman, P.; et al. A Large-Scale North American Study of Fungal Isolates from Nails: The Frequency of Onychomycosis, Fungal Distribution, and Antifungal Susceptibility Patterns. J. Am. Acad. Dermatol. 2000, 43, 641–648. [Google Scholar] [CrossRef] [PubMed]
  22. Gupta, A.K.; Gupta, G.; Jain, H.C.; Lynde, C.W.; Foley, K.A.; Daigle, D.; Cooper, E.A.; Summerbell, R.C. The Prevalence of Unsuspected Onychomycosis and Its Causative Organisms in a Multicentre Canadian Sample of 30 000 Patients Visiting Physicians’ Offices. J. Eur. Acad. Dermatol. Venereol. 2016, 30, 1567–1572. [Google Scholar] [CrossRef] [PubMed]
  23. Landreau, A.; Simon, L.; Delaunay, P.; Pomares, C.; Hasseine, L. Superficial Fungal Infections in the South of France—Is Fusariosis the next Emergent Onychopathy? Med. Mycol. 2023, 61, myad015. [Google Scholar] [CrossRef]
  24. Navarro-Pérez, D.; García-Oreja, S.; Tardáguila-García, A.; León-Herce, D.; Álvaro-Afonso, F.J.; Lázaro-Martínez, J.L. Microbiological Culture Combined with PCR for the Diagnosis of Onychomycosis: Descriptive Analysis of 121 Patients. Mycoses 2023, 66, 1045–1049. [Google Scholar] [CrossRef]
  25. Hirose, M.; Noguchi, H.; Yaguchi, T.; Matsumoto, T.; Hiruma, M.; Fukushima, S.; Ihn, H. Onychomycosis Caused by Aspergillus subramanianii. J. Dermatol. 2018, 45, 1362–1366. [Google Scholar] [CrossRef]
  26. Takahata, Y.; Hiruma, M.; Sugita, T.; Muto, M. A Case of Onychomycosis Due to Aspergillus sydowii Diagnosed Using DNA Sequence Analysis. Mycoses 2008, 51, 170–173. [Google Scholar] [CrossRef]
  27. Ma, M.; Liao, J. Aspergillus in Onychomycosis. Available online: https://proceedings.med.ucla.edu/wp-content/uploads/2021/02/Liao-A201118JL-BLM-formatted.pdf (accessed on 30 August 2024).
  28. Gupta, A.K.; Stec, N.; Summerbell, R.C.; Shear, N.H.; Piguet, V.; Tosti, A.; Piraccini, B.M. Onychomycosis: A Review. J. Eur. Acad. Dermatol. Venereol. 2020, 34, 1972–1990. [Google Scholar] [CrossRef]
  29. Otašević, S.; Barac, A.; Pekmezovic, M.; Tasic, S.; Ignjatović, A.; Momčilović, S.; Stojanović, P.; Arsic Arsenijevic, V.; Hay, R. The Prevalence of Candida Onychomycosis in Southeastern Serbia from 2011 to 2015. Mycoses 2016, 59, 167–172. [Google Scholar] [CrossRef] [PubMed]
  30. Widaty, S.; Miranda, E.; Bramono, K.; Menaldi, S.L.; Marissa, M.; Oktarina, C.; Surya, D.; Kusumawardhani, H.T. Prognostic Factors Influencing the Treatment Outcome of Onychomycosis Candida. Mycoses 2020, 63, 71–77. [Google Scholar] [CrossRef]
  31. Feng, X.; Ling, B.; Yang, X.; Liao, W.; Pan, W.; Yao, Z. Molecular Identification of Candida Species Isolated from Onychomycosis in Shanghai, China. Mycopathologia 2015, 180, 365–371. [Google Scholar] [CrossRef]
  32. Fich, F.; Abarzúa-Araya, A.; Pérez, M.; Nauhm, Y.; León, E. Candida parapsilosis and Candida guillermondii: Emerging Pathogens in Nail Candidiasis. Indian J. Dermatol. 2014, 59, 24–29. [Google Scholar] [CrossRef] [PubMed]
  33. Lipner, S.R.; Falotico, J.M.; Konda, A. On the Basis of Sex: Impact and Treatment of Toenail Onychomycosis in Female Patients. J. Clin. Aesthet. Dermatol. 2023, 16, 52–57. [Google Scholar]
  34. Benedict, K.; Lipner, S.R.; Caplan, A.S.; Gold, J.A.W. Household Transmission of Tinea Infections: Analysis of a Large Commercial Health Insurance Claims Database, United States, 2021. Open Forum Infect. Dis. 2024, 11, ofae334. [Google Scholar] [CrossRef] [PubMed]
  35. Albucker, S.J.; Falotico, J.M.; Choo, Z.-N.; Matushansky, J.T.; Lipner, S.R. Risk Factors and Treatment Trends for Onychomycosis: A Case-Control Study of Onychomycosis Patients in the All of Us Research Program. J. Fungi 2023, 9, 712. [Google Scholar] [CrossRef] [PubMed]
  36. Moseley, I.; Ragi, S.D.; Ouellette, S.; Rao, B. Onychomycosis in Underrepresented Groups: An All of Us Database Analysis. Arch. Dermatol. Res. 2023, 315, 647–651. [Google Scholar] [CrossRef]
  37. Gupta, A.K. (University of Toronto, Toronto, ON, Canada; Mediprobe Research Inc., London, ON, Canada); Bakotic, W.L. (Bako Diagnostics, GA, USA). Unpublished work. 2024. [Google Scholar]
Figure 1. PAS-stained nail specimens: (A,D) a subungual infection pattern evidenced by the presence of fungal elements in the subungual keratin; (B,E) a superficial infection pattern evidenced by the presence of fungal elements within the dorsal aspect of the nail plate; and (C,F) a dystrophic infection pattern evidenced by the presence of fungal elements in the nail plate and in the subungual keratin. Fungal elements are indicated by black arrows.
Figure 1. PAS-stained nail specimens: (A,D) a subungual infection pattern evidenced by the presence of fungal elements in the subungual keratin; (B,E) a superficial infection pattern evidenced by the presence of fungal elements within the dorsal aspect of the nail plate; and (C,F) a dystrophic infection pattern evidenced by the presence of fungal elements in the nail plate and in the subungual keratin. Fungal elements are indicated by black arrows.
Jof 10 00633 g001
Figure 2. Distribution of fungal agents in patients with mycology-confirmed onychomycosis diagnoses by PCR and histopathology. Results are stratified by year and presented as mean ± SD; mixed detections and un-speciated samples are not shown.
Figure 2. Distribution of fungal agents in patients with mycology-confirmed onychomycosis diagnoses by PCR and histopathology. Results are stratified by year and presented as mean ± SD; mixed detections and un-speciated samples are not shown.
Jof 10 00633 g002
Figure 3. Likelihood of: (A) NDMs; and (B) yeasts in causing subungual onychomycosis, with moderate-to-florid fungal element quantities, compared to dermatophytes. Data points represent OR (95% CI), grey-shaded bars represent the prevalence of the respective NDM/yeast target, the reference (dotted) line represents dermatophytes with an OR of 1.
Figure 3. Likelihood of: (A) NDMs; and (B) yeasts in causing subungual onychomycosis, with moderate-to-florid fungal element quantities, compared to dermatophytes. Data points represent OR (95% CI), grey-shaded bars represent the prevalence of the respective NDM/yeast target, the reference (dotted) line represents dermatophytes with an OR of 1.
Jof 10 00633 g003
Figure 4. Likelihood of: (A) NDMs; and (B) yeasts in causing superficial onychomycosis compared to dermatophytes. Data points represent OR (95% CI), grey-shaded bars represent the prevalence of the respective NDM/yeast target, the reference (dotted) line represents dermatophytes with an OR of 1.
Figure 4. Likelihood of: (A) NDMs; and (B) yeasts in causing superficial onychomycosis compared to dermatophytes. Data points represent OR (95% CI), grey-shaded bars represent the prevalence of the respective NDM/yeast target, the reference (dotted) line represents dermatophytes with an OR of 1.
Jof 10 00633 g004
Figure 5. Likelihood of: (A) NDMs; and (B) yeasts in causing dystrophic onychomycosis compared to dermatophytes. Data points represent OR (95% CI), grey-shaded bars represent the prevalence of the respective NDM/yeast target, the reference (dotted) line represents dermatophytes with an OR of 1.
Figure 5. Likelihood of: (A) NDMs; and (B) yeasts in causing dystrophic onychomycosis compared to dermatophytes. Data points represent OR (95% CI), grey-shaded bars represent the prevalence of the respective NDM/yeast target, the reference (dotted) line represents dermatophytes with an OR of 1.
Jof 10 00633 g005
Table 1. Likelihood of contracting dermatophyte onychomycosis per patient sex, age group, and U.S. census region.
Table 1. Likelihood of contracting dermatophyte onychomycosis per patient sex, age group, and U.S. census region.
VariableDermatophytesT. rubrum ComplexT. mentagrophytes Complex
N%OR (95% CI)N%OR (95% CI)N%OR (95% CI)
Sex
    Male128,75146.7Referent111,61240.5Referent10,9854.0Referent
    Female98,88923.00.3 (0.3, 0.3)82,09519.10.3 (0.3, 0.4)12,2832.90.7 (0.7, 0.7)
Age group
    <18 years547727.70.6 (0.6, 0.6)521026.40.6 (0.6, 0.7)550.30.2 (0.2, 0.3)
    18–44 years57,88839.2Referent53,44636.2Referent20291.4Referent
    45–64 years83,87732.20.7 (0.7, 0.7)72,69527.90.7 (0.7, 0.7)71442.72.0 (1.9, 2.1)
    ≥65 years81,94829.50.7 (0.6, 0.7)63,57722.90.5 (0.5, 0.5)14,2395.13.9 (3.7, 4.1)
Region
    Northeast72,64634.71.1 (1.1, 1.1)62,81830.01.1 (1.1, 1.2)66173.20.9 (0.9, 0.9)
    Midwest34,00532.2Referent28,82727.3Referent36763.5Referent
    South103,04630.40.9 (0.9, 0.9)86,99725.70.9 (0.9, 0.9)10,8363.20.9 (0.9, 1.0)
    West19,79134.91.1 (1.1, 1.2)16,61729.31.1 (1.1, 1.1)23344.11.2 (1.1, 1.3)
OR ≤ 0.5 or ≥1.5 are shown in bold.
Table 2. Likelihood of contracting non-dermatophyte mold onychomycosis per patient sex, age group and U.S. census region.
Table 2. Likelihood of contracting non-dermatophyte mold onychomycosis per patient sex, age group and U.S. census region.
VariableNDMsAspergillusFusarium
N%OR (95% CI)N%OR (95% CI)N%OR (95% CI)
Sex
    Male195207.1Referent32061.5Referent29331.4Referent
    Female5555612.92.0 (1.9, 2.0)15,6214.73.3 (3.1, 3.4)90572.72.0 (1.9, 2.1)
Age group
    <18 years12266.20.7 (0.7, 0.8)530.30.1 (0.1, 0.2)3092.00.8 (0.7, 0.9)
    18–44 years12,1988.3Referent26662.3Referent30192.6Referent
    45–64 years27,99310.71.3 (1.3, 1.4)61853.11.4 (1.3, 1.4)49062.51.0 (0.9, 1.0)
    ≥65 years34,40712.41.6 (1.5, 1.6)10,1524.82.2 (2.1, 2.3)38591.80.7 (0.7, 0.7)
Region
    Northeast17,1278.20.8 (0.7, 0.8)38762.40.9 (0.9, 1.0)34362.10.8 (0.8, 0.9)
    Midwest10,97610.4Referent21182.6Referent20862.6Referent
    South42,59912.61.2 (1.2, 1.3)11,3174.41.7 (1.6, 1.8)61212.40.9 (0.9, 1.0)
    West49268.70.8 (0.8, 0.9)16513.71.4 (1.3, 1.5)4641.00.4 (0.4, 0.4)
VariableAcremoniumScopulariopsisNeoscytalidium
N%OR (95% CI)N%OR (95% CI)N%OR (95% CI)
Sex
    Male4490.2Referent3390.2Referent9390.4Referent
    Female5410.20.8 (0.7, 0.9)4450.10.8 (0.7, 1.0)12320.40.8 (0.8, 0.9)
Age group
    <18 years30.00.3 (0.1, 0.8)80.10.7 (0.3, 1.5)40.00.2 (0.1, 0.5)
    18–44 years870.1Referent840.1Referent1780.2Referent
    45–64 years3630.22.5 (1.9, 3.1)2740.11.9 (1.5, 2.5)8250.42.7 (2.3, 3.2)
    ≥65 years5420.33.5 (2.8, 4.4)4300.22.9 (2.3, 3.6)11940.63.8 (3.2, 4.4)
Region
    Northeast2430.10.7 (0.5, 0.8)1840.10.5 (0.4, 0.6)9960.64.8 (3.9, 5.9)
    Midwest1840.2Referent1950.2Referent1040.1Referent
    South4570.20.8 (0.7, 0.9)3350.10.5 (0.5, 0.6)9830.43.0 (2.4, 3.7)
    West1110.21.1 (0.9, 1.4)790.20.7 (0.6, 1.0)1030.21.8 (1.4, 2.4)
OR ≤ 0.5 or ≥1.5 are shown in bold. NDM, non-dermatophyte mold.
Table 3. Likelihood of contracting yeast onychomycosis per patient sex, age group and U.S. census region.
Table 3. Likelihood of contracting yeast onychomycosis per patient sex, age group and U.S. census region.
VariableYeastsC. albicansC. parapsilosis
N%OR (95% CI)N%OR (95% CI)N%OR (95% CI)
Sex
    Male68062.5Referent5490.2Referent38491.4Referent
    Female15,9283.71.5 (1.5, 1.6)17190.42.0 (1.8, 2.2)96982.31.6 (1.6, 1.7)
Age group
    <18 years3731.90.9 (0.8, 1.0)220.10.5 (0.3, 0.8)1860.90.7 (0.6, 0.8)
    18–44 years32382.2Referent3130.2Referent20071.4Referent
    45–64 years86313.31.5 (1.5, 1.6)8430.31.5 (1.3, 1.7)52862.01.5 (1.4, 1.6)
    ≥65 years10,8323.91.8 (1.7, 1.9)11130.41.9 (1.7, 2.2)62512.31.7 (1.6, 1.8)
Region
    Northeast68663.31.3 (1.2, 1.3)6600.31.0 (0.9, 1.1)44802.11.5 (1.4, 1.6)
    Midwest27542.6Referent3420.3Referent14971.4Referent
    South11,9023.51.4 (1.3, 1.4)11090.31.0 (0.9, 1.1)69982.11.5 (1.4, 1.6)
    West13982.50.9 (0.9, 1.0)1660.30.9 (0.8, 1.1)6931.20.9 (0.8, 0.9)
OR ≤ 0.5 or ≥1.5 are shown in bold.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Gupta, A.K.; Wang, T.; Polla Ravi, S.; Mann, A.; Lincoln, S.A.; Foreman, H.-C.; Bakotic, W.L. Epidemiology of Onychomycosis in the United States Characterized Using Molecular Methods, 2015–2024. J. Fungi 2024, 10, 633. https://doi.org/10.3390/jof10090633

AMA Style

Gupta AK, Wang T, Polla Ravi S, Mann A, Lincoln SA, Foreman H-C, Bakotic WL. Epidemiology of Onychomycosis in the United States Characterized Using Molecular Methods, 2015–2024. Journal of Fungi. 2024; 10(9):633. https://doi.org/10.3390/jof10090633

Chicago/Turabian Style

Gupta, Aditya K., Tong Wang, Shruthi Polla Ravi, Avantika Mann, Sara A. Lincoln, Hui-Chen Foreman, and Wayne L. Bakotic. 2024. "Epidemiology of Onychomycosis in the United States Characterized Using Molecular Methods, 2015–2024" Journal of Fungi 10, no. 9: 633. https://doi.org/10.3390/jof10090633

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop